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drug (ATD) treatment [5], or to occur or worsen after a 
period of uncontrolled hypothyroidism [6]. Accordingly, 
the European Group on Graves’ Orbitopathy (EUGOGO) 
Consensus Statement few years ago recommended that res-
toration and maintenance of euthyroidism are priorities in 
Graves’ disease patients with GO [7]. How to treat hyper-
thyroidism when GO is present is, however, a challenging 
dilemma [8]. Are current modalities for hyperthyroidism 
[ATDs, radioiodine (RAI), thyroidectomy] per se capable 
to affect the course of GO? If orbital disease is present, is 
it preferable to control hyperthyroidism with ATDs or may 
thyroid ablation (RAI, thyroidectomy, alone or in associa-
tion) be advantageous by removing factors (thyroid auto-
reactive lymphocytes, thyroid antigens) that may promote 
the occurrence and/or progression of GO? To address these 
questions, the Italian Society of Endocrinology established 
a task force of experts with the aim of reviewing the avail-
able literature and drawing conclusions based on evidence 
summary of recommendations is presented in Table 1.
Methods
Literature search
The major source of data acquisition included PubMed 
search strategies. Papers published in the last 35 years were 
screened. In addition, the bibliographies of relevant cita-
tions and chapters of major textbooks were evaluated for 
any additional appropriate citation.
Grading
The GRADE system was used to make recommendations 
and express the quality of the evidence [9]. The task force 
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Introduction
Graves’ disease is the most frequent form of hyperthyroid-
ism in iodine sufficient countries [1], and Graves’ orbitop-
athy (GO) is its most important and common extrathyroi-
dal manifestation [2], affecting about 25 % of patients [3]. 
Although GO is generally mild and rarely progressive [4], 
thyroid dysfunction, both hyperthyroidism and hypothy-
roidism, can influence its course. GO has been reported to 
improve after correction of hyperthyroidism with antithyroid 
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used the following coding system: (1) indicates a strong 
recommendation and is associated with the sentence “we 
recommend”; (2) denotes a weak recommendation and is 
associated with the sentence “we suggest”. Evidence grad-
ing: ØOOO denotes very low quality evidence; ØØOO, low 
quality; ØØØO, moderate quality; ØØØØ, high quality.
Effects of different modalities of treatment 
for hyperthyroidism on GO
Antithyroid drugs
ATDs (thionamides: methimazole, carbimazole, propylthi-
ouracil) are the first-line treatment for Graves’ hyperthy-
roidism in Europe [10] and Japan [11], while North Ameri-
cans still prefer RAI [11], although the use of ATDs is 
lately increasing in USA as well [12]. ATDs usually bear 
a low rate of adverse events, but their major drawback is 
the high frequency of disease recurrences [13–15]. ATDs 
per se do not appear to influence the natural course of GO 
once euthyroidism has been restored. In a randomized 
control trial comparing RAI and ATDs, most patients had 
stable GO during ATD treatment [16], with a few cases of 
progression or remission compatible the natural history of 
the disease. This was confirmed by a recent observational, 
prospective study of a large series of newly diagnosed 
Graves’ patients undergoing an 18-month course of ATDs 
[3]. ATDs might, however, beneficially affect GO only as a 
consequence of the restoration of euthyroidism [5] and the 
associated progressive reduction in TSH-receptor antibody 
(TRAb) concentrations [17]. Fluctuations of thyroid status 
in fact may negatively affect GO. Therefore, assessment of 
thyroid status should be frequent (every 6–8 weeks) dur-
ing the initial phases of treatment (or after changes in daily 
dose of the ATD) and periodical (every 3–4 months) there-
after. Hypothyroidism can also cause progression of GO 
[6]. There is no evidence that the choice of the regimen 
of ATD treatment (titration method vs. block-and-replace 
method) makes any difference in terms of GO course.
Recommendation 1 We recommend that in patients with 
newly diagnosed Graves’ hyperthyroidism, euthyroidism be 
Table 1  Summary of recommendations
Recommendation 
number
Statement Strength and level 
of evidence
1 In patients with newly diagnosed Graves’ hyperthyroidism, euthyroidism should be promptly restored 
by antithyroid drugs, and then stably maintained
1, ØØØØ
2 Thyroid status should be assessed frequently during the initial phase of antithyroid drug treatment 
and regularly thereafter, to avoid fluctuations in thyroid status potentially detrimental for GO
1, ØØØO
3 Steroid prophylaxis is recommended in patients receiving radioiodine treatment, if mild and active 
GO preexists or there are risk factors for radioiodine-associated GO development or progression
1, ØØØØ
4 Pros and cons of steroid prophylaxis after radioiodine treatment should be thoroughly discussed also 
with patients with absent or inactive GO prior to radioiodine treatment
1, ØOOO
5 If surgery is selected, near-total/thyroid thyroidectomy should be preferred to subtotal thyroidectomy, 
because the former is associated with a higher rate of successful treatment of hyperthyroidism, with 
no differences in the outcome of GO; steroid prophylaxis is not required
1, ØØØØ
6 If surgery for Graves’ hyperthyroidism is selected in patients with GO, post-operative remnant abla-
tion may be considered, because this inactivates the disease earlier and allows prompter rehabilita-
tive surgery, if needed
2, ØØØO
7 Patients who have mild and active GO and are treated with antithyroid drugs should receive a 
6-month selenium supplementation
1, ØØØO
8 The modality of treatment for hyperthyroidism in patients with mild and active GO should be 
selected independently of GO
1, ØOOO
9 The modality of treatment for hyperthyroidism in patients with mild and inactive GO should be 
selected independently of GO
1, ØOOO
10 In patients with moderate-to-severe and active GO, treatment of GO should be priority, and euthy-
roidism should be promptly restored and stably maintained
1, ØØØO
11 In patients with moderate-to-severe and active GO, large, multicenter randomized clinical trials 
should be designed to establish whether the conservative or the ablative approach is preferable for 
the long-term outcome of GO
1, ØOOO
12 In patients with moderate-to-severe and inactive GO, treatment of hyperthyroidism should be inde-
pendent of residual GO manifestations
1, ØØOO
13 Hyperthyroid patients with sight-threatening GO should be treated with antithyroid drugs until dys-
thyroid optic neuropathy or corneal breakdown is cured and GO is inactive
1, ØØOO
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promptly restored by ATDs, and then stably maintained (1, 
ØØØØ);
Recommendation 2 We recommend that thyroid sta-
tus be assessed frequently during the initial phase of ATD 
treatment and regularly thereafter, to avoid fluctuations in 
thyroid status potentially detrimental for GO (1, ØØØO).
Radioiodine
Radioiodine is an effective, widely used, and safe modal-
ity of treatment for Graves’ hyperthyroidism, employed as 
first-line therapy in North America [1, 11]. Hypothyroid-
ism develops in the large majority of patients within 1 year 
from RAI administration [18].
The effects of RAI on GO are debated, due to the limited 
number of controlled studies [19]. In a small randomized 
clinical trial, not including a control group of patients on 
ATD treatment, post-RAI worsening of GO was observed 
in about one-third of patients not receiving concomitant 
oral prednisone treatment (see below), but in none of those 
treated with prednisone [20]. Subsequently, in another 
randomized clinical trial, GO progressed more frequently 
after RAI (33 %) than after thyroidectomy (16 %) or 
ATDs (10 %) [21]. In a large randomized clinical trial on 
450 Graves’ patients, progression of GO was confirmed 
in about 15 % of patients after RAI, often transiently and 
most frequently in active smokers, but not after ATDs [16]. 
A more recent, large randomized clinical trial showed that 
both RAI and smoking are relevant risk factors for progres-
sion and also de novo development of GO [22], and smok-
ers receiving RAI treatment have the highest risk [22]. 
Severity of hyperthyroidism [21], late correction of post-
RAI hypothyroidism [23, 24], and probably, but not cer-
tainly, high TRAb concentrations [25–27] and its rise after 
RAI therapy [17] may also be relevant risk cofactors. The 
absence of GO prior to RAI administration does not rule 
out the possibility of its occurrence after RAI treatment 
[22], but the risk of progression is higher in patients with 
preexisting GO [16]. Recent onset of hyperthyroidism may 
represent an additional risk factor and should be taken into 
account, particularly if patients are given RAI as first-line 
treatment [22, 27].
In patients at risk of RAI-associated GO occurrence or 
progression, oral steroid prophylaxis is almost universally 
effective [28]. This was shown by two randomized clini-
cal trials [16, 22] and confirmed by two meta-analyses [29, 
30]. Steroid prophylaxis can be carried out using very low 
doses of prednisone (0.2 mg/kg bodyweight), given 1 day 
after RAI therapy, gradually tapered down and withdrawn 
after 6 weeks [31]. As indicated by the results of a recent 
meta-analysis of 8 trials including 850 patients, steroid 
prophylaxis probably can be avoided in patients with absent 
or inactive GO [30]. This is particularly true if other risk 
factors for RAI-associated progression of GO are absent 
[7]. As mentioned above, short duration of Graves’ hyper-
thyroidism, might represent an important case in favor of 
steroid prophylaxis also in these patients [27]. Because GO 
may newly occur after RAI treatment, it is always wise to 
discuss the pros and cons of steroid prophylaxis also in this 
category of patients [32].
Recommendation 3 We recommend steroid prophylaxis 
in patients receiving RAI treatment, if mild and active GO 
preexists or there are risk factors for RAI-associated GO 
development or progression (1, ØØØØ);
Recommendation 4 We recommend that pros and cons of 
steroid prophylaxis after RAI treatment be thoroughly dis-
cussed also with patients with absent or inactive GO prior 
to RAI treatment (1, ØOOO);
Thyroidectomy
Thyroidectomy is an effective, but less commonly used 
modality of treatment for Graves’ hyperthyroidism [1, 
11]. As shown by three meta-analyses, near-total or 
total thyroidectomy is associated with a lower incidence 
of relapsing hyperthyroidism [33–35], with no [33] or 
minor [34, 35] differences in the rate of complications 
(hypoparathyroidism, laryngeal nerve palsy). Accord-
ingly, near-total/total thyroidectomy, performed by a 
skilled surgeon, should be regarded as the procedure of 
choice for Graves’ patients. A recent systematic review 
of existing literature suggested that surgery is more suc-
cessful than RAI, as the definitive treatment for Graves’ 
hyperthyroidism [36].
As to the effects of thyroid surgery on GO, a rand-
omized clinical trial [21] showed that the rate of de novo 
occurrence or progression of GO among patients submit-
ted to subtotal thyroidectomy or ATD treatment was simi-
lar, but significantly lower than that observed after RAI 
treatment. In a case–control prospective study, near-total 
thyroidectomy did not cause significant variations in ocu-
lar involvement in 17 of 18 patients, possibly due to short-
term release of thyroid antigens and immediate removal of 
autoreactive T lymphocytes [37]. A prospective study of 48 
Graves’ patients treated by total thyroidectomy showed that 
GO improved after surgery in 90 % of patients with preex-
isting GO [38]. A recent meta-analysis of randomized clini-
cal trials failed to show any significant difference between 
total thyroidectomy and subtotal thyroidectomy with regard 
to the course of GO [35].
Recommendation 5 We recommend that, if surgery is 
selected, near-total/thyroid thyroidectomy should be pre-
ferred to subtotal thyroidectomy, because the former is 
associated with a higher rate of successful treatment of 
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hyperthyroidism and with no differences in the outcome of 
GO; steroid prophylaxis is not required (1, ØØØØ).
Total thyroid ablation
Surgery and RAI treatment can be used sequentially to 
achieve total thyroid ablation (TTA), as in patients with 
differentiated thyroid cancer. The latter might be ben-
eficial for GO through complete removal of autoreactive 
T lymphocytes and thyroid antigen(s) shared by the thy-
roid gland and the orbital tissue probably involved in the 
pathogenesis of GO [39]. A randomized clinical trial of 
60 patients with mild to moderate-severe and active GO 
were treated with near-total thyroidectomy alone or TTA, 
and concomitantly received intravenous glucocorticoids 
combined with orbital radiotherapy for GO [40]. TTA was 
associated with a short-term better GO outcome (particu-
larly on lid aperture and exophthalmos) [40]. However, 
a follow-study on the same series failed to show signifi-
cant differences in the long term [41]. A recent prospec-
tive, randomized, single-blind clinical trial on 40 patients 
(treated with intravenous glucocorticoids for moderate-to-
severe GO) showed that TTA was more effective than sur-
gery alone in achieving an earlier and steady improvement 
of GO [42]. Neither study [40, 42] was performed in the 
absence of a concomitant treatment for GO. Two retro-
spective studies also suggested beneficial effects of TTA 
on GO [43, 44]. Evidence on the effects of early TTA in 
patients with no or mild GO is lacking.
Recommendation 6 We suggest that, if surgery for 
Graves’ hyperthyroidism is selected in patients with GO, 
post-operative remnant ablation be considered, because this 
inactivates the disease earlier and allows prompter rehabili-
tative surgery, if needed (2, ØØØO).
Choice of thyroid treatment in patients with GO
The natural history of GO is characterized by an early 
inflammatory phase (active GO), a plateau phase, and a 
spontaneous (although incomplete) remission (inactive 
GO), the whole cycle likely lasting 18–24 months [2]. 
Assessment of activity relies on a useful, although imper-
fect tool, the Clinical Activity Score (CAS), which includes 
7 items (eyelid edema, eyelid erythema, conjunctival red-
ness, chemosis, edema of the caruncle, spontaneous ocular 
pain, pain with ocular movements): GO is considered active 
if at least three out of seven items are present (CAS ≥ 3/7) 
[7]. Assessment of severity is based on a global evaluation 
of soft tissue changes, exophthalmos, ocular dysmotil-
ity, optic nerve involvement, and corneal breakdown [7]. 
Accordingly, GO can be active or inactive, mild, moderate-
to-severe, or sight-threatening [7].
Mild and active GO
A wait-and-see strategy is sufficient in most cases, although 
occasional patients may need immunosuppressive treat-
ment [7], because of a negative impact on their quality of 
life [45, 46]. A recent randomized clinical trial of patients 
treated with ATDs showed that a 6-month selenium sup-
plementation helps to improve mild GO and to prevent its 
progression to more severe forms, and is devoid of any rel-
evant side effect [47]. Selenium supplementation might be 
useful also in patients who have mild and active GO and are 
treated with RAI or thyroidectomy, but this remains to be 
demonstrated [48]. Treatment of hyperthyroidism in these 
patients is independent of GO and relies on established cri-
teria (age, goiter size, first episode of hyperthyroidism vs. 
relapse, patient’s preference, etc.) [14] or regional differ-
ences [1, 11]. For the time being, there is no evidence from 
randomized clinical trials that the long-term outcome of 
GO is better using ATDs or thyroid ablation. Steroid proph-
ylaxis is indicated in selected cases only if RAI treatment is 
selected [30].
Recommendation 7 We recommend that patients who 
have mild and active GO and are treated with ATDs receive 
a 6-month selenium supplementation (1, ØØØO).
Recommendation 8 We recommend that the modality 
of treatment for hyperthyroidism in patients with mild and 
active GO be selected independently of GO (1, ØOOO).
Mild and inactive GO
In these patients rehabilitative surgery for cosmetic or func-
tional reasons (orbital decompression, squint surgery, eye-
lid surgery) may be needed. Treatment for hyperthyroidism 
is unlikely to cause ocular changes and, therefore, is chosen 
independently of GO [8]. If RAI treatment is selected, ster-
oid prophylaxis is not indicated unless risk factors for RAI-
associated GO progression exist [30].
Recommendation 9 We recommend that the modality 
of treatment for hyperthyroidism in patients with mild and 
inactive GO be selected independently of GO (1, ØOOO).
Moderate-to-severe and active GO
These patients should receive prompt therapies for GO, 
because treatment outcome is inversely correlated to dis-
ease duration [2]. Glucocorticoids, preferably administered 
through the intravenous route [49, 50], represent the first-
line treatment, with or without associated orbital radio-
therapy [51, 52]. Novel treatments are under evaluation. 
Among them, rituximab [53]: two recent randomized clini-
cal trials have provided conflicting results, no effect [54] vs 
beneficial effect [55], indicates the need for larger multi-
center studies. The choice of the optimal thyroid treatment 
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in these patients is a matter of debate. Although not sup-
ported by randomized clinical trials, an important argument 
in favor of ATDs is that prompt correction of hyperthy-
roidism and stable maintenance of euthyroidism, usually 
achieved with ATDs, are per se beneficial for GO [5]. 
Accordingly, one line of thinking is that treatment of GO 
should be the priority, while patients are long-term treated 
with ATDs and definitive treatment for hyperthyroidism, 
if needed, is postponed after inactivation and cure of GO 
[56, 57]. On the other hand, ATD treatment is associated 
with a high relapse rate after drug withdrawal [1], and the 
continuing thyroid activity and fluctuations in thyroid sta-
tus might negatively influence the course of GO [5, 39]. 
Thus, a second line of thinking suggests that, after control 
of hyperthyroidism with ATDs, even in these patients the 
thyroid should be ablated while GO is concomitantly man-
aged with immunosuppression [40–44]. Even if two rand-
omized clinical trials suggest a short-term advantage of this 
approach, long-term results are not fully convincing. For 
the time being, evidence is lacking as to the superiority of 
the conservative approach over the ablative approach and 
vice versa. Accordingly, appropriately powered randomized 
clinical trials should be performed to address this important 
issue.
Recommendation 10 We recommend that in patients 
with moderate-to-severe and active GO, treatment of GO 
should be priority, and euthyroidism should be promptly 
restored and stably maintained (1, ØØØO).
Recommendation 11 We recommend that in patients 
with moderate-to-severe and active GO, large, multicenter 
randomized clinical trials be designed to establish whether 
the conservative or the ablative approach is preferable for 
the long-term outcome of GO (1, ØOOO).
Moderate-to-severe and inactive GO
In these patients the choice of thyroid treatment is on stand-
ard criteria largely independent of GO. If RAI is selected, 
steroid prophylaxis can be avoided if other risk factors for 
RAI-associated GO progression, particularly smoking, 
are absent [30]. A strict post-RAI follow-up is needed to 
avoid periods of persisting hyperthyroidism or uncontrolled 
hypothyroidism [23, 24].
Recommendation 12 We recommend that in patients 
with moderate-to-severe and inactive GO, treatment of 
hyperthyroidism is independent of residual GO manifesta-
tions (1, ØØOO).
Sight-threatening GO
This is a real endocrine emergency because patients are 
at risk of sight loss due to dysthyroid optic neuropathy 
(DON) and/or corneal breakdown. Therefore, they should 
immediately be treated with high-dose intravenous glu-
cocorticoids and subsequent orbital decompression if 
response to steroids is poor or absent within 2–4 weeks [58, 
59] or if there are signs of persistent inflammatory activ-
ity or optic disc swelling. Hyperthyroidism must be treated 
with ATDs and definitive treatment with RAI or thyroid-
ectomy, if needed, postponed until DON and/or corneal 
breakdown has been cured and GO is inactive [7].
Recommendation 13 We recommend that hyperthyroid 
patients with sight-threatening GO be treated with ATDs 
until DON or corneal breakdown is cured and GO is inac-
tive (1, ØØOO).
Conclusions
Optimal treatment of hyperthyroidism due to Graves’ dis-
ease in patients with associated GO remains an unsolved 
dilemma in many instances, because of the scarcity of ran-
domized clinical trials. When GO is mild (either active or 
inactive) or when GO is moderate-to-severe, but stably 
inactive, treatment of hyperthyroidism is largely independ-
ent of GO and based on established criteria. If GO is sight-
threatening, its treatment should be immediate, and hyper-
thyroidism should be controlled with ATDs. The major 
field of controversy is represented by moderate-to-severe 
and active GO, because GO should be promptly treated, 
but it is unclear whether management of hyperthyroidism 
should preferably be conservative or ablative.
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